Top

Published in:

01-03-2018 | Clinical Study

Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

Authors: Wenyin Shi, Erik S. Blomain, Joshua Siglin, Joshua D. Palmer, Tu Dan, Yang Wang, Maria Werner-Wasik, Jon Glass, Lyndon Kim, Voichita Bar Ad, Deepak Bhamidipati, James J. Evans, Kevin Judy, Christopher J. Farrell, David W. Andrews

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.

Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii93–iii101CrossRefPubMed

Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V et al. (2015) Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better. J Neurooncol 124:215–221CrossRefPubMed

Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085–4091CrossRefPubMedPubMedCentral

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708CrossRefPubMedPubMedCentral

Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H et al (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 28:334–340CrossRefPubMed

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA et al (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed

Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740CrossRefPubMed

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729CrossRefPubMed

Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259CrossRefPubMed

10.

Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206CrossRefPubMedPubMedCentral

11.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745CrossRefPubMed

12.

Hundsberger T, Reardon DA, Wen PY (2017) Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 17:507–515CrossRefPubMed

13.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787CrossRefPubMed

14.

Magnuson W, Ian Robins H, Mohindra P, Howard S (2014) Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. J Neurooncol 117:133–139CrossRefPubMed

15.

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053CrossRefPubMedPubMedCentral

16.

Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173CrossRefPubMed

17.

Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL et al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163CrossRefPubMedPubMedCentral

18.

Park KJ, Kano H, Iyer A, Liu X, Niranjan A, Flickinger JC et al (2012) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol 107:323–333CrossRefPubMed

19.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB et al (2012) Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 82:2018–2024CrossRefPubMed

20.

Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D (2005) Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol 181:768–773CrossRefPubMed

21.

Combs SE, Gutwein S, Thilmann C, Huber P, Debus J, Schulz-Ertner D (2005) Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neuro-oncol 74:167–171CrossRef

22.

Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P et al (2015) Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122:559–566CrossRefPubMed

23.

Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD et al (2014) Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience. Neurooncol Pract 1:172–177PubMedPubMedCentral

24.

Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefPubMed

25.

Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511–519CrossRefPubMed

26.

Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy?. Strahlenther Onkol 185:235–240CrossRefPubMed

27.

Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23:155–159CrossRefPubMed

28.

Patel M, Siddiqui F, Jin JY, Mikkelsen T, Rosenblum M, Movsas B et al (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol 92:185–191CrossRefPubMed

29.

Torcuator RG, Thind R, Patel M, Mohan YS, Anderson J, Doyle T et al (2010) The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97:401–407CrossRefPubMed

30.

Sarmey N, Chao ST, murphy ES, Yu JS, Peereboom D, Stevens G et al (2015) The role of salvage radiation in recurrent glioblastoma after bevacizumab failure. ASCO Annual Meeting, Chicago, IL

Title: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment
Authors: Wenyin Shi
Erik S. Blomain
Joshua Siglin
Joshua D. Palmer
Tu Dan
Yang Wang
Maria Werner-Wasik
Jon Glass
Lyndon Kim
Voichita Bar Ad
Deepak Bhamidipati
James J. Evans
Kevin Judy
Christopher J. Farrell
David W. Andrews
Publication date: 01-03-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2709-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis

P2Y14 receptor activation decreases interleukin-6 production and glioma GL261 cell proliferation in microglial transwell cultures

Executive functioning, academic skills, and quality of life in pediatric patients with brain tumors post-proton radiation therapy

SNF5 as a prognostic factor in skull base chordoma

External validity of two nomograms for predicting distant brain failure after radiosurgery for brain metastases in a bi-institutional independent patient cohort

A case of unusually long survival after leptomeningeal carcinomatosis diagnosis